Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 31, Issue 3, 2016, Pages 404-409

  Ameis, Helen M ^a   Drenckhan, Astrid ^b   Freytag, Morton ^b   Izbicki, Jakob R ^b   Supuran, Claudiu T ^c   Reinshagen, Konrad ^a   Holland Cunz, Stefan ^d   Gros, Stephanie J ^b,d  

^a Altonaer Kinderkrankenhaus   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; FC5 207A; FC8 325A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TUMOR ANTIGEN;

ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CHILD; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; INFANT; METABOLISM; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; STRUCTURE ACTIVITY RELATION; SURVIVAL ANALYSIS; TUMOR CELL CULTURE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASE IX; CARBONIC ANHYDRASES; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INFANT; INFANT, NEWBORN; MOLECULAR STRUCTURE; NEUROBLASTOMA; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 84962616708     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2015.1029471     Document Type: Article

References (40)

1. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
2. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8:278-92.
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
4. Ciccarone V, Spengler BA, Meyers MB, et al. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 1989;49:219-25.
5. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
6. Castleberry RP, Pritchard J, Ambros P, et al. The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer 1997;33:2113-16.
7. Fukuda M, Miyajima Y, Miyashita Y, Horibe K. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study. J Pediatr Hematol Oncol 2001;23:10-13.
8. Hero B, Simon T, Horz S, Berthold F. Metastatic neuroblastoma in infancy: what does the pattern of metastases contribute to prognosis? Med Pediatr Oncol 2000;35:683-7.
9. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
10. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
11. Pinkerton CR, Blanc Vincent MP, Bergeron C, et al. Induction chemotherapy in metastatic neuroblastoma-does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC). Eur J Cancer 2000;36:1808-15.
12. Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2000;18:4067-76.
13. Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364-76.
14. Fiaschi T, Giannoni E, Taddei ML, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013;12:1791-801.
15. Jung JH, Im S, Jung ES, Kang CS. Clinicopathological implications of the expression of hypoxia-related proteins in gastric cancer. Int J Med Sci 2013;10:1217-23.
16. Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, et al. Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients. J Oral Pathol Med 2012;41:667-74.
17. Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 2013;32:5210-19.
18. Dungwa JV, Hunt LP, Ramani P. Carbonic anhydrase IX upregulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas. Hum Pathol 2012;43:1651-60.
19. Jogi A, Vallon-Christersson J, Holmquist L, et al. Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. Exp Cell Res 2004; 295:469-87.
20. Hussein D, Estlin EJ, Dive C, Makin GW. Chronic hypoxia promotes hypoxia-inducible factor-1 alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 2006;5: 2241-50.
21. Hughes M, Marsden HB, Palmer MK. Histologic patterns of neuroblastoma related to prognosis and clinical staging. Cancer 1974;34:1706-11.
22. Lutz W, Stohr M, Schurmann J, et al. Conditional expression of N-myc in human neuroblastoma cells increases expression of alphaprothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996;13:803-12.
23. Lutz W, Fulda S, Jeremias I, et al. MycN and IFN gamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998;17: 339-46.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
25. Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumorassociated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005;48:4834-41.
26. Jubb AM, Buffa FM, Harris AL. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 2010;14:18-29.
27. Kato Y, Yashiro M, Noda S, et al. Expression of a hypoxiaassociated protein, carbonic anhydrase-9, correlates with malignant phenotypes of gastric carcinoma. Digestion 2010;82:246-51.
28. Luo Y, Cai J, Xue H, et al. Functional SDF1 alpha/CXCR4 signaling in the developing spinal cord. J Neurochem 2005;93:452-62.
29. Schweiger T, Kollmann D, Nikolowsky C, et al. Carbonic anhydrase IX is associated with early pulmonary spreading of primary colorectal carcinoma and tobacco smoking. Eur J Cardiothorac Surg 2014;46:92-9.
30. Birner P, Jesch B, Friedrich J, et al. Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression. Ann Surg Oncol 2011;18:3330-7.
31. Tanaka N, Kato H, Inose T, et al. Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer 2008;99:1468-75.
32. Fiaschi T, Giannoni E, Taddei ML, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013;12: 1791-801.
33. Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364-76.
34. Chen J, Rocken C, Hoffmann J, et al. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 2005;54: 920-7.
35. Pastorekova S, Casini A, Scozzafava A, et al. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:869-73.
36. Dubois L, Lieuwes NG, Maresca A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol 2009;92:423-8.
37. Dubois L, Peeters S, Lieuwes NG, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 2011;99:424-31.
38. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993;11:738-50.
39. Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011;29:121-6.
40. van Dijk J, Uemura H, Beniers AJ, et al. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 1994;56: 262-8.